找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology; Witold Lasek,Radoslaw Zagozdzon Book 2016 The Author(s) 20

[復(fù)制鏈接]
樓主: Harrison
11#
發(fā)表于 2025-3-23 10:47:31 | 只看該作者
Antitumor Effects of IL-12 in Preclinical Studies,Immunother 63: 419–435, .). To further attenuate IL-12-induced toxicities, in many recent preclinical treatment schemes, gene therapy approaches have been tested in which the IL-12 gene is introduced in various viral and non-viral vectors. Some of these approaches have been and are being applied in
12#
發(fā)表于 2025-3-23 14:53:41 | 只看該作者
Clinical Trials with IL-12 in Cancer Immunotherapy,on induced severe side effects. In fact, only few studies reported promising results with sporadic overt tumor regressions (apart from patients with AIDS-associated Kaposi sarcoma). Due to the low response to IL-12 and its high toxicity, accrual to some trials was even stopped (Motzer et al. in Jour
13#
發(fā)表于 2025-3-23 19:18:34 | 只看該作者
Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology
14#
發(fā)表于 2025-3-24 01:54:01 | 只看該作者
15#
發(fā)表于 2025-3-24 04:53:17 | 只看該作者
16#
發(fā)表于 2025-3-24 07:38:21 | 只看該作者
17#
發(fā)表于 2025-3-24 13:04:47 | 只看該作者
Witold Lasek,Radoslaw ZagozdzonExplores the biology of interleukin 12 and its potential in cancer therapy.Discusses antitumor effects identified in preclinical studies and clinical trials in cancer immunotherapy.Is particularly rel
18#
發(fā)表于 2025-3-24 17:28:04 | 只看該作者
SpringerBriefs in Immunologyhttp://image.papertrans.cn/i/image/471136.jpg
19#
發(fā)表于 2025-3-24 20:10:04 | 只看該作者
20#
發(fā)表于 2025-3-25 01:23:55 | 只看該作者
Andrew Kwok-Fai Lui,Sin-Chun Ng,Yin-Chun Fungame time, but the number of users is limited by the multiuser interference (MUI) (see, e.g. [54]) due to the fact that the spread spectrum codes are not orthogonal. In real systems, not only the number of users increases the MUI but we also have to deal with the relative distances of them from the r
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 01:28
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
仁化县| 梁山县| 康乐县| 丽江市| 麻江县| 佛学| 依兰县| 石城县| 林州市| 双流县| 五指山市| 合山市| 汝城县| 桃源县| 罗定市| 宜昌市| 赣州市| 泾源县| 壤塘县| 岳阳市| 齐齐哈尔市| 雅江县| 鄱阳县| 邵武市| 辽宁省| 改则县| 黄龙县| 茌平县| 沁水县| 霸州市| 册亨县| 六安市| 阳城县| 衡山县| 台湾省| 三亚市| 淳化县| 蒙阴县| 施秉县| 长白| 南雄市|